Medifast, Inc.
MED · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.94 | -0.25 | -1.06 | 0.25 |
| FCF Yield | 8.84% | 19.30% | 13.78% | 2.46% |
| EV / EBITDA | 7.56 | 4.73 | 6.28 | 10.67 |
| Quality | ||||
| ROIC | 0.70% | 43.66% | 79.60% | 69.83% |
| Gross Margin | 73.80% | 72.37% | 71.34% | 73.89% |
| Cash Conversion Ratio | 11.71 | 1.49 | 1.36 | 0.58 |
| Growth | ||||
| Revenue 3-Year CAGR | -27.77% | -11.10% | 19.58% | 28.83% |
| Free Cash Flow Growth | -87.94% | -20.64% | 194.83% | -56.69% |
| Safety | ||||
| Net Debt / EBITDA | -4.80 | -0.52 | -0.31 | -0.32 |
| Interest Coverage | 0.00 | 0.00 | 263.63 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.72 | 5.43 | 3.85 | 2.21 |
| Cash Conversion Cycle | 44.79 | 18.97 | 52.37 | 99.98 |